4.61

4.54% +0.20

After Hours: 4.61

Inozyme Pharma Inc (INZY)

Overview News Price History Option Chain Discussions Forecast

Inozyme Pharma Inc stock is currently priced at $4.61, with a 24-hour trading volume of 509.83K. It has seen a +4.54% increased in the last 24 hours and a -36.94% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.45 pivot point. If it approaches the $4.62 resistance level, significant changes may occur.

Previous Close:

$4.41

Open:

$4.44

24h Volume:

509.83K

Market Cap:

$284.77M

Revenue:

Net Income/Loss:

$-71.17M

P/E Ratio:

-2.9742

EPS:

-1.55

Net Cash Flow:

$-70.97M

1W Performance:

+4.77%

1M Performance:

-36.94%

6M Performance:

+59.52%

1Y Performance:

-20.65%

1D Range:

$4.35

$4.715

52W Range:

$2.689

$7.795

Inozyme Pharma Inc Stock (INZY) Company Profile

Name

Inozyme Pharma Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

Address

700 Technology Square, Floor 2, Cambridge

Employee

Twitter

Next Earnings Date

2024-05-07

Latest SEC Filings

INZY's Discussions on Twitter

Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-23	Upgrade	Jefferies	Hold → Buy
May-26-22	Initiated	Jefferies	Hold
Feb-07-22	Initiated	H.C. Wainwright	Buy
Nov-29-21	Initiated	Needham	Buy
Aug-18-20	Initiated	BofA Securities	Buy
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Wedbush	Outperform

View All

Inozyme Pharma Inc Stock (INZY) Latest News

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

GlobeNewswire Inc.

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire Inc.

Top 5 Health Care Stocks That May Plunge In March

Benzinga

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

GlobeNewswire Inc.

Inozyme Pharma Inc Stock (INZY) Financials Data

Inozyme Pharma Inc (INZY) Net Income 2024

INZY net income (TTM) was -$71.17 million for the quarter ending December 31, 2023, a -6.13% decrease year-over-year.

Inozyme Pharma Inc (INZY) Cash Flow 2024

INZY recorded a free cash flow (TTM) of -$70.97 million for the quarter ending December 31, 2023, a -22.01% decrease year-over-year.

Inozyme Pharma Inc (INZY) Earnings per Share 2024

INZY earnings per share (TTM) was -$1.39 for the quarter ending December 31, 2023, a +26.46% growth year-over-year.

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.